The document discusses using a tobacco-based manufacturing platform for rapidly and cost-effectively producing vaccines and therapeutics. It outlines the business model, which involves licensing the technology to larger biotech companies, and describes initial customer feedback indicating the flu vaccine market may be difficult to enter but the therapeutics market, such as for alpha-1 antitrypsin, could be more promising. Prototyping efforts involve further characterizing alpha-1 antitrypsin production in tobacco plants.